Welcome to our preeclampsia project!
Predicting Preeclampsia
Preeclampsia ranks as one of the leading causes of mortality during pregnancy, accounting for approximately 500,000 infant and 70,000 maternal deaths annually. Through this project, our objective is to mitigate the negative outcomes associated with preeclampsia. By leveraging advanced predictive models, we aim to accurately assess the risk of preeclampsia in pregnant women immediately following the first trimester. This early detection approach is pivotal in enhancing maternal and infant health outcomes.
CONNECT WITH US
Impact Maternal Health
Are You Ready?
Are you an OBGYN, midwife, or nurse?
Become part of our preeclampsia journey
by contacting us
NeoPrediX AG (Switzerland)
Aeschengraben 20, 4051 Basel, Switzerland
Executive Team: Jörg Schmidt, Prof. Dr. Marc Pfister , Prof. Dr. Sven Wellmann
Registered office: Basel
Commercial register number CH-270.3.016.001-3
Chairman of the board: Dr. Gerhard Ries
NeoPrediX USA, Inc. (US)
110 E Broward Blvd #1700
Fort Lauderdale, FL 33301, United States
Phone: +1 (954)-315-3884
NeoPrediX AG (Germany)
Franz-Mayer-Straße 1, 93053 Regensburg
Excecutive Board: Thorsten Waloschek (chairman), Jörg Schmidt
Registered Office: Regensburg
Commercial register number: HRB 18679
Supervisory Board: Dr. Volker Pfahlert (chairman), Arne Kirchner, Prof. Dr. Marc Pfister, Dr. Gerhard Ries, Prof. Dr. Sven Wellmann
